These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20014363)

  • 1. Fragile X syndrome -- from genes to cognition.
    Schneider A; Hagerman RJ; Hessl D
    Dev Disabil Res Rev; 2009; 15(4):333-42. PubMed ID: 20014363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice.
    Michalon A; Bruns A; Risterucci C; Honer M; Ballard TM; Ozmen L; Jaeschke G; Wettstein JG; von Kienlin M; Künnecke B; Lindemann L
    Biol Psychiatry; 2014 Feb; 75(3):189-97. PubMed ID: 23910948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome.
    Tranfaglia MR
    Dev Neurosci; 2011; 33(5):337-48. PubMed ID: 21893938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The behavioral phenotype of FMR1 mutations.
    Boyle L; Kaufmann WE
    Am J Med Genet C Semin Med Genet; 2010 Nov; 154C(4):469-76. PubMed ID: 20981777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice.
    Vinueza Veloz MF; Buijsen RA; Willemsen R; Cupido A; Bosman LW; Koekkoek SK; Potters JW; Oostra BA; De Zeeuw CI
    Genes Brain Behav; 2012 Apr; 11(3):325-31. PubMed ID: 22257369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
    Jacquemont S; Curie A; des Portes V; Torrioli MG; Berry-Kravis E; Hagerman RJ; Ramos FJ; Cornish K; He Y; Paulding C; Neri G; Chen F; Hadjikhani N; Martinet D; Meyer J; Beckmann JS; Delange K; Brun A; Bussy G; Gasparini F; Hilse T; Floesser A; Branson J; Bilbe G; Johns D; Gomez-Mancilla B
    Sci Transl Med; 2011 Jan; 3(64):64ra1. PubMed ID: 21209411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microRNAs and Fragile X Syndrome.
    Lin SL
    Adv Exp Med Biol; 2015; 888():107-21. PubMed ID: 26663181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors.
    Nakamoto M; Nalavadi V; Epstein MP; Narayanan U; Bassell GJ; Warren ST
    Proc Natl Acad Sci U S A; 2007 Sep; 104(39):15537-42. PubMed ID: 17881561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
    Yan QJ; Rammal M; Tranfaglia M; Bauchwitz RP
    Neuropharmacology; 2005 Dec; 49(7):1053-66. PubMed ID: 16054174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragile X syndrome: a review of clinical and molecular diagnoses.
    Ciaccio C; Fontana L; Milani D; Tabano S; Miozzo M; Esposito S
    Ital J Pediatr; 2017 Apr; 43(1):39. PubMed ID: 28420439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragile X syndrome in females - a familial case report and review of the literature.
    Stembalska A; Łaczmańska I; Gil J; Pesz KA
    Dev Period Med; 2016; 20(2):99-104. PubMed ID: 27442693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Language development and fragile X syndrome: profiles, syndrome-specificity, and within-syndrome differences.
    Abbeduto L; Brady N; Kover ST
    Ment Retard Dev Disabil Res Rev; 2007; 13(1):36-46. PubMed ID: 17326110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group I metabotropic glutamate receptor mediated dynamic immune dysfunction in children with fragile X syndrome.
    Careaga M; Noyon T; Basuta K; Van de Water J; Tassone F; Hagerman RJ; Ashwood P
    J Neuroinflammation; 2014 Jun; 11():110. PubMed ID: 24942544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.
    Tsiouris JA; Brown WT
    CNS Drugs; 2004; 18(11):687-703. PubMed ID: 15330685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.
    De Rubeis S; Fernández E; Buzzi A; Di Marino D; Bagni C
    Adv Exp Med Biol; 2012; 970():517-51. PubMed ID: 22351071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.
    Michalon A; Sidorov M; Ballard TM; Ozmen L; Spooren W; Wettstein JG; Jaeschke G; Bear MF; Lindemann L
    Neuron; 2012 Apr; 74(1):49-56. PubMed ID: 22500629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of activity-mediated spine dynamics and learning impairment in a mouse model of Fragile X syndrome.
    Boda B; Mendez P; Boury-Jamot B; Magara F; Muller D
    Eur J Neurosci; 2014 Apr; 39(7):1130-7. PubMed ID: 24712992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene, brain, and behavior relationships in fragile X syndrome: evidence from neuroimaging studies.
    Lightbody AA; Reiss AL
    Dev Disabil Res Rev; 2009; 15(4):343-52. PubMed ID: 20014368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.
    Scharf SH; Jaeschke G; Wettstein JG; Lindemann L
    Curr Opin Pharmacol; 2015 Feb; 20():124-34. PubMed ID: 25488569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BDNF in fragile X syndrome.
    Castrén ML; Castrén E
    Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.